TEMPEST THERAPEUTICS INC (TPST) Stock News
NASDAQ:TPST - Nasdaq - US87978U2078 - Common Stock - Currency: USD
TPST Latest News, Press Relases and Analysis
Tempest Presents New Amezalpat MOA Data Reinforcing Its Potential as Novel Cancer Treatment at the 2025 AACR Annual Meeting
BRISBANE, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing...
Tempest Presents New Amezalpat MOA Data Reinforcing Its Potential as Novel Cancer Treatment at the 2025 AACR Annual Meeting
Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP
BRISBANE, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing...
Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP
Tempest Weighs M&A, Analyst Sees A "Broken Story" Despite Phase 2 Liver Cancer Study Success
Tempest Therapeutics hires MTS Health to explore M&A and partnerships after Roche shows limited interest in its liver cancer program.
Tempest Therapeutics Retail Chatter Explodes As Cancer Drug Developer Mulls Possible Merger
CEO Stephen Brady emphasized the company's strong data and regulatory momentum, pointing to Phase 2 results for amezalpat in advanced liver cancer and FDA clearance for a pivotal Phase 3 study.
Tempest Announces Plan to Explore Strategic Alternatives to Advance Promising Pipeline of Clinical Oncology Assets and Maximize Stockholder Value
Amezalpat (TPST-1120) is Phase 3-ready: completed FDA and EMA interactions for first-line pivotal study in hepatocellular carcinoma (HCC); global...
Tempest Reports Year End 2024 Financial Results and Provides Business Update
Tempest Reports Year End 2024 Financial Results and Provides Business Update
• Granted Both Orphan Drug & Fast Track designations for Amezalpat (TPST-1120) for the treatment of patients with Hepatocellular Carcinoma (HCC)•...
Tempest Announces Amezalpat Poster Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting
Clinical data supporting mechanism of action reinforce potential as a novel cancer treatment...
Tempest Announces Amezalpat Poster Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting
Clinical data supporting mechanism of action reinforce potential as a novel cancer treatment
FDA Study May Proceed Notice Received for Phase 2 Trial of TPST-1495 for the Treatment of Familial Adenomatous Polyposis (FAP)
Second clinical program entering Phase 2 with data expected 2026...
FDA Study May Proceed Notice Received for Phase 2 Trial of TPST-1495 for the Treatment of Familial Adenomatous Polyposis (FAP)
Second clinical program entering Phase 2 with data expected 2026
Tempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma
Fast Track Designation highlights potential of amezalpat to address unmet need for patients with HCC Amezalpat builds momentum with both Fast...
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing...
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Tempest Receives Orphan Drug Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma (HCC)
BRISBANE, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing...
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing...
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Tempest to Participate in the Piper Sandler 36th Annual Healthcare Conference
BRISBANE, Calif., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing...
Tempest to Participate in the Piper Sandler 36th Annual Healthcare Conference
Tempest Reports Third Quarter 2024 Financial Results and Provides Business Update
Tempest Reports Third Quarter 2024 Financial Results and Provides Business Update
Building upon a successful end-of-Phase 2 meeting, received FDA “Study May Proceed” letter for pivotal Phase 3 trial of amezalpat (TPST-1120) combination...
Why Is Cancer Focused Tempest Therapeutics Stock Trading Higher On Thursday?
Tempest Therapeutics Inc. (NASDAQ:TPST) stock is trading higher on Thursday, with a strong session volume of over 23 million as per data from Benzinga Pro. The company entered into an agreement with Roche Holdings AG (OTC:RHHBY) to advance the evaluation of amezalpat (TPST-1120) in combination with atezolizumab (Tecentriq) and bevacizumab, the current standard of care for unresectable or metastatic hepatocellular carcinoma (HCC), into a Phase 3 trial for the first-line treatment of liver cancer.
Tempest Announces Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into First-Line Hepatocellular Carcinoma Pivotal Trial
The company is preparing for the Phase 3 study start in the first quarter of 2025...
Tempest Announces Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into First-Line Hepatocellular Carcinoma Pivotal Trial
The company is preparing for the Phase 3 study start in the first quarter of 2025
Tempest Extends Limited Duration Stockholder Rights Plan
BRISBANE, Calif., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest” or the “Company”), a clinical-stage...